Skip to main navigation
Skip to search
Skip to main content
Tel Aviv University Home
Update Request & User Guide (TAU staff only)
Link opens in a new tab
Search content at Tel Aviv University
Home
Experts
Research units
Research output
Datasets
Prizes
Activities
Press/Media
Current and future options in cholesterol lowering treatments
Avishay Elis
Internal Medicine
Rabin Medical Center Israel
Research output
:
Contribution to journal
›
Review article
›
peer-review
11
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Current and future options in cholesterol lowering treatments'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
LDL-C Level
100%
Cholesterol-lowering Treatment
100%
Lipid-lowering Agents
66%
Small Interfering RNA (siRNA)
33%
Therapeutic Target
33%
Cardiovascular Events
33%
Atherosclerotic Process
33%
Patient's Will
33%
Clinical Benefit
33%
Clinical High Risk
33%
Recent Changes
33%
Statins
33%
Lipid-lowering
33%
Cardiovascular Outcomes
33%
Therapeutic Regimen
33%
Relative Risk Reduction
33%
Absolute Reductions
33%
Ezetimibe
33%
Very High Cardiovascular Risk
33%
Anti-PCSK9 Monoclonal Antibodies
33%
Bempedoic Acid
33%
Early Combination
33%
Inclisiran
33%
Medicine and Dentistry
Cardiovascular System
100%
Hypolipidemic Agent
100%
Cardiovascular Risk
50%
Monoclonal Antibody
50%
Statin
50%
Small Interfering RNA
50%
Relative Risk Reduction
50%
Ezetimibe
50%
Inclisiran
50%
Bempedoic Acid
50%
Nursing and Health Professions
Antilipemic Agent
100%
Cardiovascular Risk
50%
Monoclonal Antibody
50%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
50%
Small Interfering RNA
50%
Inclisiran
50%
Ezetimibe
50%
Bempedoic Acid
50%
Pharmacology, Toxicology and Pharmaceutical Science
Antilipemic Agent
100%
Small Interfering RNA
50%
Cardiovascular Risk
50%
Monoclonal Antibody
50%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
50%
Ezetimibe
50%
Bempedoic Acid
50%
Inclisiran
50%